Ensysce Biosciences, Inc. (ENSC)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$0.8M
Cash & Equivalents
$3.5M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$4M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-08-01 Phase3 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06602271 PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) PHASE3 Recruiting 320

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ENSC.

SEC EDGAR Filings

All SEC filings for Ensysce Biosciences, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.